

IX BIOPHARMA LTD
(Incorporated in Singapore)
(Company Registration No. 200405621W)

ISSUE AND ALLOTMENT OF SHARES PURSUANT TO EXERCISE OF WARRANTS

The Board of Directors (the “**Board**”) of iX Biopharma Ltd. (the “**Company**”), and together with its subsidiaries, the “**Group**”) wishes to announce that on 27 November 2025, the Company has allotted and issued 626,844 new ordinary shares pursuant to the exercise of warrants at the exercise price of S\$0.06 per warrant share, following which the number of issued shares of the Company has increased from 955,980,766 shares to 956,607,610 shares.

The new ordinary shares rank *pari passu* in all respects with the existing shares of the Company and are expected to be listed and quoted on the Singapore Exchange Securities Trading Limited on or around 1 December 2025. Pursuant to the aforesaid exercise of warrants, there are 55,861,314 outstanding warrants with an exercise price of S\$0.06 for each warrant share expiring on 18 July 2026.

Warrant holders may refer to <https://www.ixbiopharma.com/warrants/> for instruction on how to exercise their warrants.

BY ORDER OF THE BOARD

Eddy Lee Yip Hang
Chairman & CEO
27 November 2025

*This announcement has been reviewed by the Company’s Sponsor, UOB Kay Hian Private Limited (the “**Sponsor**”).*

*This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Mr. Lance Tan, Senior Vice President, at 83 Clemenceau Avenue, #10-01, UE Square, Singapore 239920, telephone: (65) 6590 6881.